Positive safety review of Remygen[®] gives clearance to start next part of Phase I/II trial in type 1 diabetes patients

The initial safety and dose escalation part of the Phase I/II trial with Remygen[®] in type 1 diabetes patients, ReGenerate-1, has been completed. The safety data from the six patients included in this first part of the trial has been evaluated by an independent Data Safety Monitoring Board (DSMB) who recommends that the main study can start. Metabolic results from the now completed safety and dose escalation part are being compiled and will be presented later this year."We already have the first participants ready to enter the next part of the trial," says Per-Ola Carlsson, Professor at